Homology(FIXX) - 2025 Q2 - Quarterly Results

-- Strengthened leadership team with appointment of Adrien Sipos, M.D., Ph.D., an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, as Interim Chief Medical Officer -- Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update -- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 -- -- Cash and cash equivalents of $54.8 million as of June 30, 2025, which is now ex ...